We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

30 hedge funds and large institutions have $5.26M invested in Corbus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,400% more call options, than puts

Call options by funds: $260K | Put options by funds: $4K

298% more capital invested

Capital invested by funds: $1.32M → $5.26M (+$3.94M)

17.04% more ownership

Funds ownership: 0.32%17.36% (+17%)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

52% less funds holding

Funds holding: 6330 (-33)

89% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 36

Holders
30
Holders Change
-33
Holders Change %
-52.38%
% of All Funds
0.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
7
Reduced
13
Closed
36
Calls
$260K
Puts
$4K
Net Calls
+$256K
Net Calls Change
+$234K
Name Holding Trade Value Shares
Change
Change in
Stake
BAM
26
Belpointe Asset Management
Nevada
$160 +$96 +22 New
SIM
27
Studio Investment Management
Illinois
$65 -$4 -1 -10%
NA
28
NewEdge Advisors
Louisiana
$58
Bank of America
29
Bank of America
North Carolina
$7 -$48 -11 -92%
SSB
30
Sandy Spring Bank
Maryland
$7 -$4 -1 -50%
Two Sigma Investments
31
Two Sigma Investments
New York
-$63K -19,006 Closed
Acadian Asset Management
32
Acadian Asset Management
Massachusetts
-$31K -9,581 Closed
Northern Trust
33
Northern Trust
Illinois
-$22.9K -6,911 Closed
Creative Planning
34
Creative Planning
Kansas
-$22.9K -6,901 Closed
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
-$23K -5,247 Closed
LPL Financial
36
LPL Financial
California
-$17K -5,116 Closed
Renaissance Technologies
37
Renaissance Technologies
New York
-$11K -3,423 Closed
Charles Schwab
38
Charles Schwab
California
-$11K -3,314 Closed
TSS
39
Two Sigma Securities
New York
-$9.34K -2,817 Closed
Cambridge Investment Research Advisors
40
Cambridge Investment Research Advisors
Iowa
-$7K -2,225 Closed
SF
41
Synovus Financial
Georgia
-$7.29K -2,200 Closed
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
-$6K -1,877 Closed
Envestnet Asset Management
43
Envestnet Asset Management
Illinois
-$3.76K -1,133 Closed
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
-$4K -1,090 Closed
Bank of New York Mellon
45
Bank of New York Mellon
New York
-$3.54K -1,069 Closed
SPC
46
Sigma Planning Corp
Michigan
-$3.54K -1,067 Closed
Mercer Global Advisors
47
Mercer Global Advisors
Colorado
-$4K -1,058 Closed
CWA
48
CJM Wealth Advisers
Virginia
-$3.37K -1,016 Closed
BRWA
49
B. Riley Wealth Advisors
Florida
-$2.37K -713 Closed
Neuberger Berman Group
50
Neuberger Berman Group
New York
-$2.21K -667 Closed

CRBP Hedge Fund Activity: Q1 2023 in Review

30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2023, worth a combined $5.26M — up 298% from $1.32M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBP and 4 opened new positions — a net loss of 32 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Ikarian Capital, adding an estimated $783K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $63K sold.

  • 30 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2023, down from 63 in Q4 2022.
  • Funds reported $5.26M of Corbus Pharmaceuticals stock for Q1 2023, up 298% quarter-over-quarter.
  • 4 funds opened new Corbus Pharmaceuticals positions in Q1 2023 and 36 closed out, a net change of -32 holders.
  • The largest Corbus Pharmaceuticals buyer in Q1 2023 was Ikarian Capital, an estimated $783K added.
  • The largest Corbus Pharmaceuticals seller in Q1 2023 was Two Sigma Investments, an estimated $63K sold.

Based on aggregated 13F filings for Q1 2023.